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Abstract 1 
The aim of this longitudinal study is to present data from 76 female patients treated with 2 
bisphosphonates for postmenopausal osteoporosis and referred to the Unit of Oral 3 
Diagnosis and Day Surgery of the University of Milano for diagnosis and treatment. 4 
All patients received a thorough oral examination. The diagnosis of osteonecrosis of the 5 
jaw bone (ONJ) was made from radiographic and clinical findings. 9% of individuals had 6 
ONJ at first visit. Patients with dental or periodontal abscess were significantly more 7 
likely to develop ONJ. Women with a positive history of diabetes had a significant 8 
increase in the odds of having ONJ (OR: 3.7, 95% CI 0.3-40.9). Patients who underwent 9 
dental extraction while receiving BPs therapy were three times more likely to develop 10 
ONJ (OR: 2.9, 95% CI 0.5-15.9). 11 
Patients with osteoporosis receiving BPs may develop ONJ, especially in the presence of 12 
an active infectious process in the mouth. Clinicians should carefully follow up on 13 
individuals receiving bisphosphonates therapy to avoid the occurrence of osteonecrotic 14 
lesions. 15 
 16 
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Introduction 1 
Postmenopausal osteoporosis is a systemic skeletal condition that affects many 2 
millions of women around the world. The National Institutes of Health Consensus 3 
Conference defined osteoporosis as a disease of increased skeletal fragility accompanied 4 
by microarchitectural deterioration and low bone mineral density (a T score for bone 5 
mineral density below –2.5) [1]. Osteoporosis prevention and treatment has relied on 6 
hormonal treatments such as estrogens and selective estrogen-receptor modulators, and 7 
on anti-catabolic drugs and bone resorption inhibitors including bisphosphonates.  8 
Bisphosphonates are the most widely used anti-catabolic agents in the pharmacological 9 
management of postmenopausal osteoporosis [2]. These compounds are potent 10 
suppressor of osteoclast activity, improve trabecular and cortical architecture and 11 
increase bone mineral density thereby [3] reducing the risk of fracture in women 12 
osteoporosis [4].  13 
Since 2003, numerous reports proposed an association between bisphosphonate 14 
use and osteonecrosis of the jaw bone as a long-term side effect of this class of agents [5]. 15 
According to the American Association of Oral and Maxillofacial Surgeons’ position 16 
paper [6], patients may be considered to have bisphosphonates-related osteonecrosis of 17 
the jaw (BRONJ) if all of the following three characteristics are present: 1) current or 18 
previous treatment with a bisphosphonate, 2) exposed, necrotic bone in the maxillofacial 19 
region that has persisted for more than eight weeks and 3) no history of radiation therapy 20 
to the jaws. 21 
Although BRONJ is a dose-related side effect and it is more common in cancer 22 
patients [7], a recent paper showed that the frequency of osteoporosis patients on oral 23 
 4 
BPs affected by BRONJ was higher than previously reported (N=470, 7.8%) [8]. The 1 
purpose of this longitudinal study is to present data from 76 female patients treated with 2 
bisphosphonates for postmenopausal osteoporosis and referred to the Unit of Oral 3 
Diagnosis and Day Surgery of the University of Milano for diagnosis and treatment. 4 
5 
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Materials and methods 1 
Starting in 2005, all female osteoporotic patients treated with BPs were referred to 2 
the Unit of Oral Diagnosis and Day Surgery for evaluation and management. Before the 3 
visit and treatment all patients gave written informed consent. This study was approved 4 
by the Director of the Clinic in accordance with the Declaration of Helsinki. Each patient 5 
received a thorough oral, dental and periodontal examination. Each tooth was probed at 6 
four sites (three buccally and one lingually) using a North Carolina probe to measure 7 
probing pocket depth and recession.  Recession was measured using the cementoenamel 8 
junction as a reference point. Clinical attachment level (CAL) was then calculated as 9 
probing depth plus recession. Periodontitis was based on measures of the presence and 10 
extent of CAL in at least 20% of the sites probed, CAL> 4mm. Relevant clinical data 11 
regarding BPs treatment, comorbidities, oral findings, dental treatment plan, and past and 12 
present dental therapies, were assessed. Patients were followed-up every three months for 13 
routine clinical examination, oral hygiene instructions and debridement; restorative care, 14 
periodontal, and dentoalveolar procedures were provided when needed according to the 15 
American Association of Oral and Maxillofacial Surgeons guidelines [9]. Adjustment of 16 
any ill-fitting dentures was performed, when necessary. 17 
BRONJ diagnosis and staging 18 
BRONJ diagnosis was made from radiographic and clinical findings. Patients were 19 
classified as having stage 0, I, II, or III. Briefly, patients with no clinical evidence of 20 
necrotic bone were considered stage 0. Individuals were included in the stage I group if 21 
they had asymptomatic exposed bone without any evidence of infection. Stage II group 22 
patients had exposed necrotic bone with clinical evidence of infection. Finally, patients 23 
 6 
were included in the stage III group if they had exposed necrotic bone with evidence of 1 
infection, pain, and one or more of the following: pathologic fracture, extra-oral fistula, 2 
or osteolysis extending to the inferior border of the mandible or sinus floor. 3 
BRONJ management 4 
The management of BRONJ aimed to reduce lesion size, soft and hard tissue 5 
inflammation and to alleviate pain. Nonsurgical treatment included wide spectrum 6 
antibiotics, antifungal agents and mouthwashes with an antimicrobial solution. Surgical 7 
treatment included debridement without mucosal elevation and removal of loose 8 
segments of bony sequestra.  9 
Statistical Analysis 10 
We described the distribution of participants’ characteristics, including demographics, 11 
smoking status, medical history and the prevalence and clinical features of BRONJ. 12 
We performed a logistic regression analysis to estimate odds ratios (ORs) and 95% CI for 13 
exposures of interest such as diabetes, hypertension, dental or periodontal abscess, 14 
multiple dental decays, periodontitis, dental extraction and the presence of ONJ. All 15 
analyses had a significance level of 0.05.16 
 7 
Results 1 
A total of 76 Caucasian women were included in this analysis. At the time of 2 
enrollment, patients ranged in age from 51 to 91 years, with a median age of 69 years 3 
(interquartile range 62-74) (Table 1). Approximately 12% of the women reported current 4 
smoking. 5 
In addition, 34.2% suffered from hypertension, 21.1% had cardiovascular disease, 5.3% 6 
of patients reported having diabetes, 5.3% were in treatment with an immunosuppressant 7 
agent and 3.9% previously underwent chemo and radiotherapy. Multiple dental decays 8 
and periodontits were present in 61.8% and 77.6% of the individuals, respectively. 9 
All patients were affected by osteoporosis and were treated with bisphosphonates. 10 
61.8% of patients were receiving Aledronate, 21.1% Clodronate, 3.9% Ibadronate or 11 
13.2% Risedronate. Patients had received BPs for a mean duration of time of 191 weeks 12 
(95% CI, 150.9-230.7).  13 
BRONJ patients 14 
Of these 76 patients, seven (9.2%) had active ONJ at first visit and were being treated in 15 
our clinics (Table 1). Three patients were classified as being stage I and four individuals 16 
were stage II. Among these, the majority (85.7%) was in the mandible while 14.3% had 17 
ONJ in the maxilla. The triggering events for ONJ were identified as previous dento-18 
alveolar surgery (n=2), local trauma from dentures (n=3) and periodontal infection (n=2). 19 
All BRONJ patients received wide spectrum antibiotic therapy and four patients 20 
underwent surgical debridement. 21 
Treatment outcome 22 
Closure of the exposure and complete remission was obtained in 4 cases out of 7.  23 
 8 
At present none of the non-ONJ patients submitted to invasive dental treatments 1 
developed ONJ signs and/or symptoms.  2 
BRONJ associated factors 3 
Individuals with dental or periodontal abscess were significantly more likely to develop 4 
ONJ (Table 2). A borderline association was present among individuals with periodontitis 5 
(p=0.05). Women with a positive history for diabetes had a significant increase in the 6 
odds of having ONJ (OR: 3.7, 95% CI 0.3-40.9). Patients who underwent dental 7 
extraction while receiving BPs therapy were three times more likely to develop ONJ 8 
(OR: 2.9, 95% CI 0.5-15.9). 9 
No significant associations were observed for the following variables: age, smoking 10 
status, type of BPs used, hypertension, cardiovascular disease, immunosuppressant, 11 
previous radio and chemotherapy and multiple dental decays. 12 
13 
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Discussion 1 
Bisphosphonates are the most widely prescribed drugs for the treatment of 2 
osteoporosis, with more than 190 million prescriptions dispensed worldwide [10]. The 3 
results of our analysis showed that the incidence of ONJ attributable to the use of 4 
bisphosphonates was 9%. Our findings are in agreement with those of Otto et al. [8], who 5 
conducted a large multicenter trial on the relationship between ONJ and the use of BPs 6 
and showed that 7.8% of cases  (N = 470) were associated with oral BPs therapy due to 7 
osteoporosis.  8 
Patients with diabetes were four times more likely to develop ONJ. The risk increased 9 
also for patients who underwent dental-alveolar procedures and for those women who 10 
had periodontal disease and dental or periodontal abscess. Our results are also consistent 11 
with those from a paper by the M. D. Anderson Cancer Center group [11], which reported 12 
that patients who had a dental or periodontal abscess, and were taking bisphosphonates, 13 
were at a seven-fold increased risk for developing BRONJ.  14 
Individuals who had dental extractions were three times more likely to be 15 
diagnosed with BRONJ. Data presented by Hoff et al.[12] showed that cancer patients 16 
with a positive history of dental extractions were associated with a significant increase in 17 
the odds of detecting ONJ (OR: 13.2; 95% CI 3.7-47.3; p < 0.0001). However, our odds 18 
ratios are lower than those reported by Hoff and colleagues.  It may be that cancer 19 
patients have a slower healing process than cancer free but osteoporotic patients; both 20 
radiation therapy and chemotherapy can affect the ability of cells to reproduce, which 21 
slows the healing process in the mouth [13]. In addition, chemotherapy may reduce the 22 
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number of white blood cells and weaken the immune system, making it easier for the 1 
patient to develop an infection. As such, the risk of ONJ is significantly increased.  2 
Though small numbers limited our ability to fully evaluate the risk factors for 3 
ONJ, no associations were observed for tobacco use, presence of multiple decays, 4 
previous radiotherapy and/or chemotherapy or concomitant use of immunosuppressant 5 
medications.  Another limitation to note for this study is that our study population was 6 
hospital-based. Therefore, our results may not be generalizable to the population at large. 7 
In order to overcome these sample-size issues, multicentric population-based case–8 
control studies are warranted.  9 
10 
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Conclusions 1 
Our findings indicate that patients with osteoporosis receiving BPs may develop 2 
osteonecrosis of the mandible, especially in the presence of an active infectious process 3 
in the mouth such as periodontal disease or suppuration. In addition, management of this 4 
condition requires the use of prolonged medical treatment and may require oral surgical 5 
procedures. As such, there is an urgent need to fill a knowledge gap in better 6 
characterizing this condition, identifying the main cause, and determining individual 7 
susceptibility for the intervention and prevention of BRONJ. To follow up on our 8 
findings, additional large clinical trials that aim to find how to overcome bisphosphonate-9 
associated ONJ and to predict who may benefit from bisphosphonate treatment without 10 
accompanying risk of ONJ are warranted.  In the meantime, patients receiving 11 
bisphosphonates therapy should be followed carefully to avoid the occurrence of 12 
extended osteonecrotic lesions.  13 
14 
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Table 1. Patients’ characteristics, osteonecrosis of the jaw and dental treatments 1 
 2 
 Total 
(N=76) 
 n (%) 
Age category  
50-60 14 (18.4) 
61-70 27 (35.5) 
71-79 28 (36.9) 
80+ 7 (9.2) 
Median [IQR]  69 [62-74] 
Smoking status  
Never 56 (73.7) 
Current 9 (11.8) 
Former 11 (14.5) 
MEDICAL HISTORY 
Hypertension  
No 50 (65.8) 
Yes 26 (34.2) 
Cardiovascular disease 
No 60 (78.9) 
Yes 16 (21.1) 
Immunosuppressant  
No 72 (94.7) 
Yes 4 (5.3) 
Previous Radio/Chemotherapy 
No 73 (96.1) 
Yes 3 (3.9) 
BPs and BRONJ  
BPs treatment  
Alendronate 47 (61.8) 
Clodronate 16 (21.1) 
Ibandronate 3 (3.9) 
Risendronate 10 (13.2) 
ONJ at first visit  
No 69 (90.8) 
Yes 7 (9.2) 
ONJ Stage  
0 57 (89.1) 
I 3 (4.7) 
II 4 (6.3) 
ONJ Site  
 16 
Maxilla 1 (14.3) 
Jaw Bone 6 (85.7) 
ORAL CARE 
Minor ONJ surgery  
No 72 (94.7) 
Yes 4 (5.3) 
Dental treatment  
No 31 (40.8) 
Yes 45 (59.2) 
Abbreviations: ONJ: Osteonecrosis of the jaw; BP’s: Bisphosphonates. 1 
2 
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Table 2. Univariate analysis of associations with osteonecrosis of the jaw bone 1 
  ONJ   
 
Total 
(N=76) 
No 
(N=69) 
Yes 
(N=7) 
Odds ratio 
(95%CI) 
P value 
 n (%) n (%) n (%)   
Diabetes      
0.26 No 72 (94.7) 66 (91.7) 6 (8.3) 1.0 
Yes 4 (5.3) 3 (75.0) 1 (25.0) 3.7 (0.3-40.9) 
Hypertension      
0.24 No 50 (65.8) 44 (88.0) 6 (12.0) 1.0 
Yes 26 (34.2) 25 (96.2) 1 (3.8) 0.3 (0.1-2.6) 
Suppuration      
<0.01 No 70 (92.1) 69 (98.6) 1 (1.4) 1.0 
Yes 6 (7.9) 0 (0.0) 6 (100.0) ∞ (<0.001-∞) 
Multiple dental decays      
0.06 No 29 (38.2) 24 (82.8) 5 (17.2) 1.0 
Yes 47 (61.8) 45 (95.7) 2 (4.3) 0.2 (0.1-1.2) 
Periodontitis      
0.05 No 17 (22.4) 17 (100.0) 0 (0.0) 1.0 
Yes 59 (77.6) 52 (88.1) 7 (11.9) ∞ (<0.001-∞) 
Dental extraction      
0.20 No 39 (51.3) 37 (94.9) 2 (5.1) 1.0 
Yes 37 (48.7) 32 (86.5) 5 (13.5) 2.9 (0.5-15.9) 
Abbreviation: ONJ: osteonecrosis of the jaw 2 
